Drugs / M-001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03058692 | Apr 2018 → Jan 2019 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Mixed |
| Phase 2 | NCT02293317 | Nov 2014 → Mar 2015 | influenza | BiondVax Pharmaceuticals ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03450915 | Aug 2018 → Jul 2020 | influenza | BiondVax Pharmaceuticals ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M-001 | “The M-001 vaccine consists of 3 repetitions of 9 conserved linear epitopes that are prepared as a single recombinant protein.” NCT03058692 ↗ |
| Known as | Multimeric-001 | “Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine” NCT03058692 ↗ |
| Modality | Vaccine | “A recombinant epitope based universal vaccine against seasonal and pandemic influenza” NCT02293317 ↗ |
| Route | Intramuscular | “M-001 (0.5mg) administered intramuscular 3 times at 21 days intervals” NCT02293317 ↗ |